News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
5,938 Results
Type
Article (581)
Company Profile (2)
Press Release (5355)
Section
Business (1105)
Career Advice (6)
Deals (227)
Drug Development (539)
Employer Resources (1)
FDA (548)
Job Trends (104)
News (2513)
Policy (225)
Tag
Academia (30)
Accelerated approval (1)
Alliances (259)
Alzheimer's disease (12)
Approvals (549)
Artificial intelligence (5)
Bankruptcy (1)
Best Places to Work (83)
Brain cancer (2)
Breast cancer (3)
Cancer (9)
Cardiovascular disease (14)
Career advice (6)
Clinical research (504)
Collaboration (4)
Compensation (4)
Complete response letters (1)
COVID-19 (9)
C-suite (4)
Data (56)
Depression (2)
Diabetes (1)
Diagnostics (22)
Digital health (1)
Duchenne muscular dystrophy (3)
Earnings (432)
Employer resources (1)
Events (661)
Executive appointments (6)
FDA (593)
Funding (13)
Gene therapy (6)
GLP-1 (4)
Government (32)
Guidances (5)
Healthcare (100)
Huntington's disease (3)
Immunology and inflammation (2)
Infectious disease (11)
Inflammatory bowel disease (1)
Intellectual property (2)
Interviews (4)
IPO (60)
Job creations (23)
Job search strategy (3)
Labor market (1)
Layoffs (1)
Legal (30)
Liver cancer (1)
Longevity (1)
Lymphoma (1)
Management (1)
Manufacturing (1)
Medical device (272)
Medtech (272)
Mergers & acquisitions (176)
Metabolic disorders (16)
Multiple sclerosis (2)
Neuropsychiatric disorders (2)
Neuroscience (42)
NextGen: Class of 2025 (43)
Non-profit (22)
Obesity (14)
Opinion (1)
Parkinson's disease (6)
Patents (8)
Patient recruitment (2)
People (395)
Pharmaceutical (1)
Phase I (92)
Phase II (197)
Phase III (218)
Pipeline (41)
Policy (2)
Postmarket research (53)
Preclinical (40)
Rare diseases (7)
Real estate (24)
Regulatory (216)
Research institute (20)
RNA editing (1)
Schizophrenia (14)
Series A (1)
Series B (3)
Special edition (1)
Sponsored (1)
Startups (20)
Supply chain (1)
The Weekly (1)
Vaccines (4)
Venture capital (1)
Weight loss (2)
Date
Today (3)
Last 7 days (7)
Last 30 days (16)
Last 365 days (261)
2025 (255)
2024 (293)
2023 (299)
2022 (375)
2021 (394)
2020 (332)
2019 (377)
2018 (286)
2017 (312)
2016 (319)
2015 (374)
2014 (282)
2013 (249)
2012 (265)
2011 (289)
2010 (275)
Location
Africa (1)
Arizona (4)
Asia (138)
Australia (17)
California (79)
Canada (40)
China (1)
Colorado (7)
Connecticut (22)
Delaware (4)
Europe (800)
Florida (5)
Georgia (2)
Illinois (15)
Japan (3)
Kansas (1)
Maine (5)
Maryland (10)
Massachusetts (88)
Michigan (1)
Minnesota (2)
Missouri (2)
Nevada (4)
New Jersey (21)
New York (7)
North Carolina (36)
Northern California (30)
Ohio (1)
Pennsylvania (28)
South America (6)
South Carolina (9)
Southern California (39)
Tennessee (2)
Texas (7)
United States (358)
Utah (3)
Washington State (1)
5,938 Results for "rhythm".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
FDA Action Alert: GSK, Aldeyra, Rhythm and More
Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant, which it rejected last September, triggering a very public dispute with the company.
December 15, 2025
·
5 min read
·
Tristan Manalac
Press Releases
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
November 10, 2025
·
9 min read
Press Releases
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
December 11, 2025
·
7 min read
Press Releases
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
November 5, 2025
·
23 min read
Press Releases
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
November 10, 2025
·
8 min read
Obesity
Rhythm Drug Leads to Reduced BMI in Rare Obesity Indication
Stifel analysts were bullish on the data, which showed a 16.5% drop in body-mass index among patients with damage to the hypothalamus taking Rhythm Pharmaceuticals’ Imcivree.
April 7, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
December 11, 2025
·
11 min read
Press Releases
Rhythm Pharmaceuticals to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 21, 2025
·
7 min read
Press Releases
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
November 5, 2025
·
8 min read
Press Releases
Rhythm Pharmaceuticals Announces Participation in Upcoming September 2025 Investor Conferences
August 28, 2025
·
8 min read
1 of 594
Next
